Hasil Pencarian - Peter W.M. Johnson
- Menampilkan 1 - 5 hasil dari 5
-
1
Anti-CD20 monoclonal antibodies: historical and future perspectives oleh Sean H. Lim, Stephen A. Beers, Ruth R. French, Peter W.M. Johnson, Martin J. Glennie, Mark S. Cragg
Diterbitkan 2010-01-01
Artikel -
2
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma oleh Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W.M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford
Diterbitkan 2020-01-01
Artikel -
3
Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma oleh Charles N. Birts, Constantinos Savva, Stéphanie A. Laversin, Alicia Lefas, Jamie Krishnan, Aron Schapira, Margaret Ashton-Key, Max Crispin, Peter W. M. Johnson, Jeremy P. Blaydes, Ellen Copson, Ramsey I. Cutress, Stephen A. Beers
Diterbitkan 2022-05-01
Artikel -
4
RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial oleh Sean H. Lim, Kim M. Linton, Graham P. Collins, Joke Dhondt, Joshua Caddy, Liz Rossiter, Karan Vadher, Keira Fines, Laura E. Rogers, Diana Fernando, Louise Stanton, Andrew J. Davies, Peter W. M. Johnson, Gareth Griffiths
Diterbitkan 2018-11-01
Artikel -
5
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lym... oleh Simon Rule, Paul Smith, Peter W.M. Johnson, Simon Bolam, George Follows, Joanne Gambell, Peter Hillmen, Andrew Jack, Stephen Johnson, Amy A Kirkwood, Anton Kruger, Christopher Pocock, John F. Seymour, Milena Toncheva, Jan Walewski, David Linch
Diterbitkan 2016-02-01
Artikel